2-(1,1-dimethylethyl)-4-methylisoquinolin-1(2H)-one | 1034760-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(1,1-dimethylethyl)-4-methylisoquinolin-1(2H)-one
• 英文别名: 2-Tert-butyl-4-methylisoquinolin-1-one
• CAS: 1034760-37-6
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: APEFNFQDJCLCKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-(1,1-dimethylethyl)-2-(2-methoxy-1-methylethenyl)benzamide 在 氢碘酸 作用下， 以 乙腈 为溶剂， 反应 1.5h， 以69%的产率得到2-(1,1-dimethylethyl)-4-methylisoquinolin-1(2H)-one
  参考文献：
  名称：

  Synthesis of 2,4-Disubstituted Isoquinolin-1(2H)-ones Based on Reactions of a-Substituted 2-Lithio-b-methoxystyrenes with Isocyanates

  摘要：

  An efficient method for the preparation of 2,4-disubstituted isoquinolin-1(2H)-ones is described. The reaction of alpha-substituted 2-lithio-beta-methoxystyrenes, generated by treating alpha-substituted 2-bromo-beta-methoxystyrenes with butyllithium, with isocyanates yields the corresponding a-substituted 2-(2-methoxyvinyl)benzamide derivatives, which in turn are transformed into 2,4-disubstituted isoquinolin-1(2H)-ones on treatment with a catalytic amount of concentrated hydriodic acid.

  DOI：

  10.3987/com-07-11304

文献信息

• LIGAND-CONJUGATED MONOMERS
  申请人：MANOHARAN Muthiah

  公开号：US20090286973A1

  公开（公告）日：2009-11-19

  This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

  这项发明涉及用于抑制基因表达的化学修饰寡核苷酸制剂的组成和制备方法。
• MODIFIED iRNA AGENTS
  申请人：MANOHARAN Muthiah

  公开号：US20100179309A1

  公开（公告）日：2010-07-15

  The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

  本发明涉及iRNA剂，其中最好包括一个单体，其中核糖基团已被替换为除核糖外的基团。包含这样的单体可以允许调节iRNA剂的某种特性，例如，通过使用非核糖基团作为配体或其他实体（例如，碳水化合物或类固醇，例如胆固醇，可选择地取代至少一个碳水化合物）的点来直接或间接地牵引。本发明还涉及制备和使用这种修改的iRNA剂的方法。
• Methods and compositions for treating neurological disease
  申请人：Aronin Neil

  公开号：US20070161591A1

  公开（公告）日：2007-07-12

  This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases.
• Therapeutic Compositions
  申请人：Manoharan Muthiah

  公开号：US20070275914A1

  公开（公告）日：2007-11-29

  Therapeutic sRNA agents and methods of making and using are enclosed.
• METHOD OF TREATING NEURODEGENERATIVE DISEASE
  申请人：Bumcrot David

  公开号：US20110092565A1

  公开（公告）日：2011-04-21

  Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.